Revolution Medicines Began Pancreatic Cancer Trial

The clinical trial evaluates a dual-drug combination for patients with a specific genetic mutation.

Updated on Oct. 5, 2026 in Cancer

Isometric editorial illustration of a complex molecular structure using bold geometric blocks, representing pharmaceutical research into cancer treatments. — Revolution Medicines has launched a Phase 3 clinical trial comparing a dual-drug combination to standard treatments for patients with metastatic pancreatic cancer. AI Illustration. Upload story photo >

Live Poll

Do you believe current medical research investment is doing enough to treat terminal cancer cases?

Revolution Medicines has begun treating patients in a Phase 3 clinical trial for metastatic pancreatic adenocarcinoma. The study evaluates the combination of daraxonrasib and zoldonrasib in adults with the RAS G12D mutation.

Why it matters

Preclinical data indicates this dual therapy achieves deeper suppression of RAS signaling than single agents, potentially addressing a critical gap in treatment options. Currently, no targeted therapy is approved for patients with this specific genetic variant.

The RAS G12D mutation occurs in 40% of patients diagnosed with pancreatic adenocarcinoma, a condition affecting 55,000 Americans annually. Serious adverse reactions were observed in 30% of patients treated with daraxonrasib in prior study contexts.

The players

Revolution Medicines

This Redwood City, California-based clinical-stage company focuses on developing novel targeted therapies for RAS-addicted cancers.

The details

The global, open-label trial compares the dual therapy against standard gemcitabine and nab-paclitaxel regimens. Researchers are measuring efficacy through dual primary endpoints consisting of progression-free survival and overall survival.

October 5, 2026: The company began treating patients in the trial.
August 2026: Revolution Medicines filed its most recent quarterly report.

Cancer
Sept. 22
FDA Approved New Pancreatic Cancer Drug Daraxonrasib
Cancer
Sept. 30
Researchers Identified Pancreatic Cancer Drug Resistance
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib

Health Landscape

This trial represents a shift toward precision oncology by directly addressing the RAS G12D mutation, which characterizes 40% of pancreatic cancer cases. The study builds on historical efforts to suppress RAS signaling, which has long been considered a primary driver of tumor growth.

Patients with metastatic pancreatic adenocarcinoma may eventually gain access to a targeted therapy if the trial proves successful. In the meantime, participants in the study will be monitored closely for adverse reactions, which were noted in 30% of cases in earlier phases.

The takeaway

This trial marks a significant move toward targeted, mutation-specific treatments for one of the most aggressive forms of cancer. Patients and their families should discuss the implications of clinical trial participation with their oncology teams.